Navidea Biopharmaceuticals Inc  

(Public, NYSEMKT:NAVB)   Watch this stock  
Find more results for OTC:NEOP
1.66
-0.02 (-1.19%)
Mar 30 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 1.63 - 1.70
52 week 0.97 - 2.02
Open 1.68
Vol / Avg. 0.00/565,789.00
Mkt cap 252.57M
P/E     -
Div/yield     -
EPS -0.24
Shares 150.34M
Beta 0.78
Inst. own 33%
May 5, 2015
Q1 2015 Navidea Biopharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 5, 2015
Q4 2014 Navidea Biopharmaceuticals Inc Earnings Release
Mar 5, 2015
Q4 2014 Navidea Biopharmaceuticals Inc Earnings Call - Webcast
Feb 9, 2015
Navidea Biopharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference
Jan 13, 2015
Navidea Biopharmaceuticals Inc at EBD Biotech Showcase
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -312.29% -569.36%
Operating margin -203.61% -481.97%
EBITD margin - -432.40%
Return on average assets -186.29% -136.79%
Return on average equity - -
Employees 46 -
CDP Score - -

Address

5600 Blazer Pkwy Ste 200
DUBLIN, OH 43017-7550
United States - Map
+1-614-7937500 (Phone)
+1-614-7937522 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. The Company�s radiopharmaceutical development programs included Lymphoseek (technetium Tc 99m tilmanocept) Injection is a receptor-targeted, small-molecule radiopharmaceutical used in lymphatic mapping procedures that are performed to help evaluate patients with breast cancer and melanoma; Navidea�s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on macrophages; NAV4694 is a Fluorine-18 (F-18) radiolabeled PET imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer�s disease (AD) and mild cognitive impairment (MCI); among others.

Officers and directors

Gordon A. Troup Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Ricardo J. Gonzalez Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
Brent L. Larson CPA Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Age: 51
Bio & Compensation  - Reuters
Frederick O. Cope Ph.D. Senior Vice President - Pharmaceutical Research and Clinical Development, Chief Scientific Officer
Age: 68
Bio & Compensation  - Reuters
William J. Regan Senior Vice President - Global Regulatory Affairs and Quality Chief Compliance Officer
Age: 63
Bio & Compensation  - Reuters
Thomas J. Klima Senior Vice President and Chief Commercial Officer
Age: 43
Bio & Compensation  - Reuters
Cornelia B. Reininger M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Thomas H. Tulip Ph.D. Chief Business Officer
Age: 62
Bio & Compensation  - Reuters
Michael M. Goldberg M.D. Director
Age: 56
Bio & Compensation  - Reuters
Eric K. Rowinsky M.D. Director
Age: 58
Bio & Compensation  - Reuters